DGAP-News: Epigenomics AG: Dr. Garces transitions to Company Advisor
Retrieved on:
Wednesday, January 27, 2021
Berlin (Germany) and San Diego, CA (USA), January 27, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Dr. Jorge Garces, President and Chief Scientific Officer is resigning as an Executive Board member effective January 31, 2021.
Key Points:
- Berlin (Germany) and San Diego, CA (USA), January 27, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Dr. Jorge Garces, President and Chief Scientific Officer is resigning as an Executive Board member effective January 31, 2021.
- Dr. Garces will transition to a Company Advisor role to assist the company through the end of 2021 with execution of strategic alternatives.
- "Dr. Garces has been an important member of the Epigenomics management team and the Supervisory Board is very happy to have his help as an advisor as we look to plan on strategic options for the company", said Heino von Prondzynski Chairman of the Supervisory Board of Epigenomics.
- Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology.